Abstract
Relevance. Acute respiratory infections are the leading cause of disease worldwide. Kagocel® is a synthetic antiviral agent indicated for influenza and other acute respiratory viral infections (ARVI). It induces the production of interferon, thereby enhancing the immune response to viral pathogens. Objective. To evaluate changes in quality of life and symptom dynamics when prescribing Kagocel® to patients with ARVI. Materials and methods. This open, multicenter, observational, non-interventional study enrolled 1000 adult patients, 467 with mild and 533 with moderate ARVI. All patients were prescribed Kagocel® tablets for 4 days within 24–72 h from the ARVI symptom onset. Results. In patients with mild ARVI, a statistically significant (p <0,001) improvement in the EuroQol-5 Dimension 3-level (EQ-5D-3L) score was observed by day 3, with scores increasing from 84.3±10.0 to 90.4±5.1 on day 3 and further to 95.7±4.9 by day 6. Similarly, in patients with moderate ARVI, there was also a statistically significant (p <0,001) improvement noted by day 3, with scores rising from 70.4±13.6 to 85.4±8.2 on day 3 and reaching 99.1±3.7 by day 6. By days 3 and 6, 22.1% and 88.0% of patients with mild ARVI, respectively, had no remaining symptoms. By day 3, 10.5% of patients with moderate ARVI undergoing therapy reported the absence of ARVI symptoms, and 89.9% of patients were symptom-free by day 6. No adverse events were reported. Conclusion. The oral administration of Kagocel® to ambulatory patients with mild to moderate ARVI was effective and safe; therefore, it may be routinely recommended.